دورية أكاديمية
Feasibility and acceptability of undertaking postmortem studies for tuberculosis medical research in a low income country.
| العنوان: | Feasibility and acceptability of undertaking postmortem studies for tuberculosis medical research in a low income country. |
|---|---|
| المؤلفون: | Ahimbisibwe G; Medical Research Council (MRC)/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda., Nakibuule M; Medical Research Council (MRC)/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda., Martin Ssejoba M; Medical Research Council (MRC)/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda., Oyamo D; Mulago National Referral Hospital, Kampala, Uganda., Mulwana R; Mulago National Referral Hospital, Kampala, Uganda., Nabulime J; Mulago National Referral Hospital, Kampala, Uganda., Babirye F; Mulago National Referral Hospital, Kampala, Uganda., Kizito MA; Department of Pathology, Makerere University, Kampala, Uganda., Lekuya HM; Department of Surgery, Makerere University, Kampala, Uganda., Adakun AS; Mulago National Referral Hospital, Kampala, Uganda., Nalumansi D; Mulago National Referral Hospital, Kampala, Uganda., Muryasingura S; Mulago National Referral Hospital, Kampala, Uganda., Lukande R; Department of Pathology, Makerere University, Kampala, Uganda., Kyazze A; Division of Pulmonology, Kiruddu National Referral Hospital, Kampala, Uganda., Baluku JB; Division of Pulmonology, Kiruddu National Referral Hospital, Kampala, Uganda., Biraro IA; Division of Pulmonology, Kiruddu National Referral Hospital, Kampala, Uganda.; Department of Internal Medicine, Makerere University, Kampala, Uganda., Cose S; Medical Research Council (MRC)/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda.; Clinical Research Department, London School of Hygiene and Tropical Medicine, London, United Kingdom. |
| المصدر: | Frontiers in immunology [Front Immunol] 2023 Dec 06; Vol. 14, pp. 1264351. Date of Electronic Publication: 2023 Dec 06 (Print Publication: 2023). |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Developing Countries* , Tuberculosis*, Humans ; Feasibility Studies ; Uganda ; Bronchoalveolar Lavage |
| مستخلص: | Introduction: If we are to break new ground in difficult-to-treat or difficult-to-vaccinate diseases (such as HIV, malaria, or tuberculosis), we must have a better understanding of the immune system at the site of infection in humans. For tuberculosis (TB), the initial site of infection is the lungs, but obtaining lung tissues from subjects suffering from TB has been limited to bronchoalveolar lavage (BAL) or sputum sampling, or surgical resection of diseased lung tissue. Methods: We examined the feasibility of undertaking a postmortem study for human tuberculosis research at Mulago National Referral Hospital in Kampala, Uganda. Results: Postmortem studies give us an opportunity to compare TB-involved and -uninvolved sites, for both diseased and non-diseased individuals. We report good acceptability of the next-of-kin to consent for their relative's tissue to be used for medical research; that postmortem and tissue processing can be undertaken within 8 hours following death; and that immune cells remain viable and functional up to 14 hours after death. Discussion: Postmortem procedures remain a valuable and essential tool both to establish cause of death, and to advance our medical and scientific understanding of infectious diseases. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Ahimbisibwe, Nakibuule, Martin Ssejoba, Oyamo, Mulwana, Nabulime, Babirye, Kizito, Lekuya, Adakun, Nalumansi, Muryasingura, Lukande, Kyazze, Baluku, Biraro and Cose.) |
| References: | Int J Infect Dis. 2022 Nov;124 Suppl 1:S26-S29. (PMID: 35321845) PLoS Pathog. 2016 Jul 05;12(7):e1005739. (PMID: 27379816) PLoS One. 2014 Nov 05;9(11):e111517. (PMID: 25372043) Forensic Sci Int. 2001 Dec 15;124(1):25-31. (PMID: 11741756) PLoS One. 2012;7(1):e30324. (PMID: 22295081) Respir Med. 1999 Aug;93(8):563-70. (PMID: 10542990) Trop Med Int Health. 2011 Aug;16(8):1015-8. (PMID: 21564428) Front Immunol. 2019 May 03;10:992. (PMID: 31130965) Exp Lung Res. 1996 Nov-Dec;22(6):677-90. (PMID: 8979050) Am J Respir Crit Care Med. 2016 Nov 15;194(10):1208-1218. (PMID: 27115408) BMC Infect Dis. 2015 Mar 29;15:165. (PMID: 25879423) Trends Immunol. 2015 Jul;36(7):428-35. (PMID: 26072286) Nature. 2019 Jun;570(7762):528-532. (PMID: 31168092) Clin Exp Immunol. 1998 Aug;113(2):252-7. (PMID: 9717975) J Clin Invest. 2020 Jan 2;130(1):214-230. (PMID: 31763997) Cell Rep. 2017 Sep 19;20(12):2921-2934. (PMID: 28930685) Sci Transl Med. 2014 Dec 3;6(265):265ra167. (PMID: 25473035) PLoS Med. 2016 Nov 22;13(11):e1002172. (PMID: 27875532) Nat Med. 2016 May;22(5):531-8. (PMID: 27043495) Lancet Glob Health. 2022 Sep;10(9):e1307-e1316. (PMID: 35961354) Forensic Sci Int. 1981 Mar-Apr;17(2):109-20. (PMID: 7239364) Nat Med. 2022 Dec;28(12):2622-2632. (PMID: 36411343) Immunity. 2013 Jan 24;38(1):187-97. (PMID: 23260195) Sci Transl Med. 2014 Dec 3;6(265):265ra166. (PMID: 25473034) Immunity. 2016 Feb 16;44(2):391-405. (PMID: 26850658) J Clin Invest. 2021 May 17;131(10):. (PMID: 33848273) PLoS One. 2016 Mar 31;11(3):e0151721. (PMID: 27031950) PLOS Glob Public Health. 2022 May 3;2(5):e0000076. (PMID: 36962104) Med Sci Law. 1993 Jul;33(3):213-22. (PMID: 8366783) Immunology. 2016 May;148(1):1-12. (PMID: 26778581) Eur J Immunol. 2012 Nov;42(11):2844-50. (PMID: 22821397) J Innate Immun. 2020;12(1):63-73. (PMID: 30557876) Nat Med. 2016 Oct;22(10):1094-1100. (PMID: 27595324) J Infect Dis. 2016 Nov 1;214(9):1309-1318. (PMID: 27462092) Immunity. 2017 Jan 17;46(1):148-161. (PMID: 27986455) Annu Rev Public Health. 2013;34:271-86. (PMID: 23244049) |
| معلومات مُعتمدة: | 75N93019C00070 United States AI NIAID NIH HHS; MC_UU_00027/5 United Kingdom MRC_ Medical Research Council |
| فهرسة مساهمة: | Keywords: T cells; feasibility & acceptability; postmortem studies; tissues; tuberculosis |
| تواريخ الأحداث: | Date Created: 20231222 Date Completed: 20231225 Latest Revision: 20240322 |
| رمز التحديث: | 20240322 |
| مُعرف محوري في PubMed: | PMC10734300 |
| DOI: | 10.3389/fimmu.2023.1264351 |
| PMID: | 38130719 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2023.1264351 |